Publication | Open Access

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Chemo-endocrine TherapyBreast OncologyMedicinePharmacologyGynecologyBreast CancerStage Ii-iii HormoneCancer TreatmentOncologyRadiation OncologyEndocrine-related Cancer